X.T.L. Biopharmaceuticals Ltd. - ADR Live Stock Price Today, Share Analysis and Chart

Name: X.T.L. Biopharmaceuticals Ltd. - ADR: Is Infosys Ltd. worth buying?
Item: X.T.L. Biopharmaceuticals Ltd. - ADR
Rating: 1.18450
Author: Trendlyne DVM scores

about

XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a m...

1.25 0.03 (2.46%)

51.74% Fall from 52W High

2,135

XNAS Volume

XNAS 17 Sep, 2025 10:51 AM (EDT)

Board Meeting

The next board meeting for X.T.L. Biopharmaceuticals Ltd. - ADR is on 19 Sep 2025 for the purpose of XTL Biopharmaceuticals Ltd Second Quarter Earnings Results for 2025 See details

Not Eligible

Expensive Valuation

12.0 / 100

Technically Neutral

35.4 / 100

No estimates available

XTL Biopharmaceuticals Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

X.T.L. Biopharmaceuticals Ltd. - ADR Live Stock Price Today, Share Analysis and Chart

XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a m...

51.74% Fall from 52W High

SWOT Analysis

XTL Biopharmaceuticals Live Price Chart